Bevacizumab biosimilar - AskGene Pharma

Drug Profile

Bevacizumab biosimilar - AskGene Pharma

Alternative Names: ASK B1202

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AskGene Pharma
  • Developer AskGene Pharma; Jiangsu Aosaikang Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Apr 2017 Jiangsu Aosaikang Pharmaceutical plans a phase I trial in Healthy volunteers (IV, Infusion) (NCT03115762)
  • 15 Nov 2016 Preclinical trials in Cancer in USA (IV) before November 2016
  • 15 Nov 2016 Pharmacodynamics data from preclinical trials in Cancer released by Jiangsu Aosaikang Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top